GlassScriptPhysician profile
Dan H Meirson
NPI 1518076330
$3,029.19
in general payments reported to CMS, 2019-2025
24 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 78% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $38.04 · 2021: $64.20 · 2022: $250 · 2023: $389 · 2024: $912 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,389 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,389.45 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $771.93 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $319.62 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $271.92 | 2022-2025 | Otezla, Otezla |
| Abbvie INC. | $258.17 | 2024-2025 | |
| Leo Pharma INC. | $204.31 | 2024-2025 | Anzupgo, Adbry |
| Allergan, INC. | $149.39 | 2019-2022 | |
| Pfizer INC. | $124.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $124.83 | 2019-2025 | |
| Galderma Laboratories, L.P. | $120.75 | 2019-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Biofrontera INC. | $83.61 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $70.11 | 2022-2024 | Opzelura |
| Janssen Biotech, INC. | $67.28 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $57.40 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $49.84 | 2024-2025 | Sotyktu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $44.51 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.52 | 2022-2024 | Arazlo, Cabtreo |
| Sun Pharmaceutical Industries INC. | $29.26 | 2025 | |
| Cipher Pharmaceuticals US LLC | $27.36 | 2025 | Natroba, Spinosad |
| Verrica Pharmaceuticals INC. | $26.56 | 2024 | Ycanth |
| Almirall LLC | $25.00 | 2025 | Klisyri |
| Organogenesis INC. | $24.61 | 2022 | |
| Ucb, INC. | $24.27 | 2024 | Bimzelx |
| Mylan Pharmaceuticals INC. | $16.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Meirson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.